This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Champix® (varenicline tartrate) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

Champix Safety

Prescribe Champix (varenicline) with confidence thanks to the results from EAGLES: the largest comparative study of approved smoking cessation medicines.1

Over 12 weeks of treatment with 12-week non-treatment follow up, in 8,144 smokers with or without a diagnosis of psychiatric disorders, EAGLES has shown that CHAMPIX (varenicline) has:

  • No significantly increased neuropsychiatric (NPS) safety risk vs. placebo, in smokers with or without a history of psychiatric disorders1
  • Significantly superior continuous abstinence rates vs. bupropion, NRT patch (NiQuitin® 21mg, with taper) and placebo at weeks 9-12 and 9-24 in both cohorts1

​​​​​​​CHAMPIX was not associated with a significantly increased risk of NPS adverse events vs. placebo in smokers with or without a history of psychiatric disorders.†1.

The EAGLES Trial

Watch Professor Robert West discuss the EAGLES study

Participants reporting NPS Events n/N,%1

Continuous Abstinence Rates (CAR)

CHAMPIX provides significantly superior abstinence rates vs. bupropion, NRT patch (NiQuitin® 21mg, with taper) and placebo in patients with or without a history of psychiatric disorders at weeks 9-12 (p<0.001) and at weeks 9-24 (p<0.005).1

Adapted from Anthenelli RM, et al. Lancet 2016.

Based on the all-randomised patient population. ** The primary efficacy endpoint was the CO-confirmed CAR from weeks 9-12. †† The main secondary endpoint was the CO-confirmed CAR from weeks 9-24. The other secondary endpoint was the 7-day point prevalence of abstinence at each assessment visit, which yielded results consistent with the continuous abstinence rates.

Treatment types included 1mg of varenicline twice daily vs. 150mg of bupropion twice daily vs. 21mg with taper of NiQuitin®, vs. placebo. All medications were up- or down-titrated according to prescribing information. NRT treatment was for 11 weeks.


*Evaluating Adverse Events in a Global Smoking Cessation Study

† In the psychiatric cohort, participants met DSM-IV-TR diagnostic criteria for primary affective disorders (70%), anxiety disorders (19%), psychotic disorders (9.5%) or personality disorders (0.6%). Patients had to be considered clinically stable for inclusion (i.e., no exacerbations ≤6 months; on stable treatment ≥3 months, with no treatment change anticipated during the study). In the non-psychiatric cohort, subjects were aged 18-75 years without a history of psychiatric disorders. All participants from both cohorts were randomised 1:1:1:1 to one of the 4 study treatments.  One additional participant (Psychiatric/NRT group) who reported suicidal ideation was identified after clinical database lock and was not included in this analysis.
​​​​​​​
‡ The primary safety endpoint was the incidence of a composite measure of 16 moderate and severe NPS adverse events (AEs), including anxiety, depression, feeling abnormal, and hostility (all rated as severe), and agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behaviour, and completed suicide (all rated as moderate or severe).
​​​​​​​

References:
​​​​​​​1. Anthenelli RM, et al. Lancet 2016 Apr 22. doi: 10.1016/S0140-6736(16)30272-0

PP-CHM-GBR-3360. June 2021

Champix efficacy vs NRT

Read about how Champix compares to nicotine replacement therapies.

Champix efficacy data

Resources for you

Learn more about how using Very Brief Advice (VBA) and Brief Support and Treatment (BST) can help a smoker gain the motivation and support needed, to quit successfully.

Learn more

Support material for Champix patients

Download support material for patients prescribed Champix.

Download

Quick Links

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No